EP Patent

EP4543920A1 — Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Assigned to AstraZeneca AB · Expires 2025-04-30 · 1y expired

What this patent protects

This disclosure relates to an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) and an anti-EGFR/cMET antibody molecule for use in combination in the treatment of cancer (for example, non-small cell lung cancer [NSCLC]).

USPTO Abstract

This disclosure relates to an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) and an anti-EGFR/cMET antibody molecule for use in combination in the treatment of cancer (for example, non-small cell lung cancer [NSCLC]).

Drugs covered by this patent

osimertinib-mesylate (OSIMERTINIB MESYLATE)

Patent Metadata

Patent number: EP4543920A1
Jurisdiction: EP
Classification: —
Expires: 2025-04-30
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.